Clinical trial
Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on…
NCT00253422 · Institute of Cancer Research, United Kingdom, Other · Completed
Key facts
| NCT number | NCT00253422 |
|---|---|
| Title | Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors |
| Official title | A Partially Blind Phase III Randomised Trial of Faslodex +/- Concomitant Arimidex Compared With Exemestane in Post-menopausal Women With ER+ or PR+ Locally Advanced/Metastatic Breast Cancer Following Progression on Non-steroidal AIs |
| Acronym | SoFEA |
| Lead sponsor | Institute of Cancer Research, United Kingdom, Other |
| Collaborators | Royal Marsden NHS Foundation Trust |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Anastrozole, Exemestane, Fulvestrant |
| Enrollment | 698 |
| Start date | Mar 26, 2004 |
| Primary completion | Nov 28, 2022 |
| Completion | Nov 28, 2022 |
| First posted | Nov 15, 2005 |
| Last update posted | Jun 4, 2025 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: